Efficacy of IL‐2‐ versus IL‐15‐stimulated CD8 T cells in adoptive immunotherapy
暂无分享,去创建一个
[1] E. Wherry,et al. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.
[2] C. June,et al. Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.
[3] A. Diefenbach,et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. , 2007, Immunity.
[4] T. Waldmann,et al. The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells , 2007, Proceedings of the National Academy of Sciences.
[5] C. Rooney,et al. Improving T cell therapy for cancer. , 2007, Expert opinion on biological therapy.
[6] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[7] T. Waldmann. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.
[8] Linda V. Sinclair,et al. Differential regulation of T-cell growth by IL-2 and IL-15. , 2006, Blood.
[9] C. Klebanoff,et al. CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.
[10] T. Waldmann,et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] S. Rosenberg,et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.
[12] S. Rosenberg,et al. Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .
[13] P. Burkett,et al. Coordinate Expression and Trans Presentation of Interleukin (IL)-15Rα and IL-15 Supports Natural Killer Cell and Memory CD8+ T Cell Homeostasis , 2004, The Journal of experimental medicine.
[14] J. Blattman,et al. Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.
[15] O. Bathe,et al. Initial Antigen Encounter Programs CD8+ T Cells Competent to Develop into Memory Cells That Are Activated in an Antigen-Free, IL-7- and IL-15-Rich Environment1 , 2004, The Journal of Immunology.
[16] Antonio Lanzavecchia,et al. Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.
[17] T. Waldmann,et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] L. Lefrançois,et al. Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells. , 2004, Blood.
[19] S. Larson,et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.
[20] E. Pamer,et al. Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus. , 2002, The Journal of clinical investigation.
[21] T. Waldmann,et al. IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .
[22] T. Waldmann,et al. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. , 2002, Immunity.
[23] T. Schumacher,et al. Immunotherapy through TCR gene transfer , 2001, Nature Immunology.
[24] Wolfgang Weninger,et al. Migratory Properties of Naive, Effector, and Memory Cd8+ T Cells , 2001, The Journal of experimental medicine.
[25] J. Lieberman,et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. , 2001, The Journal of clinical investigation.
[26] T. Strom,et al. IL-15 and IL-2: a matter of life and death for T cells in vivo , 2001, Nature Medicine.
[27] M. Neuenhahn,et al. Differential requirement of perforin and IFN‐γ in CD8 T cell‐mediated immune responses against B16.F10 melanoma cells expressing a viral antigen , 2000, European journal of immunology.
[28] P. Marrack,et al. Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.
[29] S. Rosenberg,et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.
[30] T. Dassopoulos,et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. , 1998, Immunity.
[31] H. Pircher,et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.
[32] D. Cosman,et al. IL‐15, a novel T cell growth factor that shares activities and receptor components with IL‐2 , 1995, Journal of leukocyte biology.
[33] Hans Hengartner,et al. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides , 1993, European journal of immunology.
[34] P. Golstein,et al. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.
[35] R M Zinkernagel,et al. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. , 1991, Journal of virological methods.
[36] S. Rosenberg,et al. Clinical effects and toxicity of interleukin‐2 in patients with cancer , 1986, Cancer.
[37] K. Smith,et al. Interleukin-2 induction of T-cell G1 progression and c-myb expression. , 1986, Science.
[38] M. Oldstone,et al. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. VI. Migration and activity in vivo in acute and persistent infection. , 1986, Journal of immunology.